Session III: AML and MDS

Moderator(s)

• 

  Gail Roboz, MD

  Weill Cornell Medicine, NewYork Presbyterian Hospital
  New York, New York, United States

Presenter(s)

• 

  Pinkal Desai, MD

  Weill Cornell Medicine
  New York, New York, United States
• 

  Tapan Kadia, MD

  MD Anderson Cancer Center
  Bellaire, Texas, United States
• 

  Amer Zeidan, MBBS, MHS

  Internal Medicine, Hematology
  Yale New Haven Health
  New Haven, Connecticut, United States

Presentations:

• 1:40 PM – 1:45 PM ET

  Welcome
• 1:45 PM – 2:05 PM ET

  Untangling Classification, Risk Assessment and Exploring Treatment Options in Low and High Risk MDS
  

  Speaker: Amer M. Zeidan, MBBS, MHS – Yale New Haven Health
• 2:05 PM – 2:25 PM ET

  Intensifying Induction Strategies in AML
  

  Speaker: Tapan Kadia, MD – MD Anderson Cancer Center
• 2:25 PM – 2:45 PM ET

  AML MRD: What to do and What to Ponder?
  

  Speaker: Gail J. Roboz, MD – Weill Cornell Medicine, NewYork Presbyterian Hospital
• 2:45 PM – 3:00 PM ET

  Debate: All Non-FLT3 Mutated AML Patients Above Age 60 with ELN Intermediate or Adverse Risk Should Be Treated with Azacitidine and Venetoclax - YES
  

  Debate Speaker: Pinkal Desai, MD – Weill Cornell Medicine
• 3:00 PM – 3:15 PM ET

  Debate: All Non-FLT3 Mutated AML Patients Above Age 60 with ELN Intermediate or Adverse Risk Should Be Treated with Azacitidine and Venetoclax - NO
  

  Debate Speaker: Tapan Kadia, MD – MD Anderson Cancer Center
• 3:15 PM – 3:35 PM ET

  Panel Discussion
  

  Moderator: Gail J. Roboz, MD – Weill Cornell Medicine, NewYork Presbyterian Hospital

  Panelist: Pinkal Desai, MD – Weill Cornell Medicine

  Panelist: Tapan Kadia, MD – MD Anderson Cancer Center

  Panelist: Amer M. Zeidan, MBBS, MHS – Yale New Haven Health